- Home
- RSKD vs OCS Comparison
RSKD vs OCS Comparison
Compare RSKD & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSKD
- OCS
- Stock Information
- Founded
- RSKD 2012
- OCS 2003
- Country
- RSKD United States
- OCS Switzerland
- Employees
- RSKD N/A
- OCS N/A
- Industry
- RSKD EDP Services
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- RSKD Technology
- OCS Health Care
- Exchange
- RSKD Nasdaq
- OCS Nasdaq
- Market Cap
- RSKD 743.4M
- OCS 869.8M
- IPO Year
- RSKD 2021
- OCS N/A
- Fundamental
- Price
- RSKD $4.67
- OCS $19.90
- Analyst Decision
- RSKD Hold
- OCS Strong Buy
- Analyst Count
- RSKD 7
- OCS 4
- Target Price
- RSKD $5.79
- OCS $41.00
- AVG Volume (30 Days)
- RSKD 487.1K
- OCS 35.1K
- Earning Date
- RSKD 11-12-2025
- OCS 11-06-2025
- Dividend Yield
- RSKD N/A
- OCS N/A
- EPS Growth
- RSKD N/A
- OCS N/A
- EPS
- RSKD N/A
- OCS N/A
- Revenue
- RSKD $335,825,000.00
- OCS $960,668.00
- Revenue This Year
- RSKD $6.27
- OCS $36.75
- Revenue Next Year
- RSKD $9.63
- OCS $1,261.53
- P/E Ratio
- RSKD N/A
- OCS N/A
- Revenue Growth
- RSKD 7.96
- OCS N/A
- 52 Week Low
- RSKD $3.94
- OCS $14.00
- 52 Week High
- RSKD $6.00
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- RSKD 44.59
- OCS 71.29
- Support Level
- RSKD $4.57
- OCS $17.26
- Resistance Level
- RSKD $4.79
- OCS $17.80
- Average True Range (ATR)
- RSKD 0.10
- OCS 0.49
- MACD
- RSKD 0.00
- OCS 0.23
- Stochastic Oscillator
- RSKD 14.81
- OCS 96.01
About RSKD Riskified Ltd.
Riskified Ltd has built a next-generation eCommerce risk management platform that allows online merchants to create trusted relationships with their consumers. It generates revenue by granting merchants access to its eCommerce risk management platform and reviewing and approving eCommerce transactions for legitimacy. Its merchants include some of the ecommerce brands including Wayfair, Lastminute.com, SHEIN, and Macy's. Its merchants operate in a variety of verticals, including Payments, Money Transfer & Crypto, Tickets & Travel, Electronics, Home, Fashion & Luxury Goods, General Retail and Food. The company derived maximum revenue from Israel.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.